Enhancement of Cytokine Production and AP-1 Transcriptional Activity in T Cells by Thalidomide-Related Immunomodulatory Drugs

CC-4047 (Actimid) and CC-5013 (Revimid) belong to a class of thalidomide analogs collectively known as the immunomodulatory drugs (IMiDs), which are currently being assessed in the treatment of patients with multiple myeloma and other cancers. IMiDs potently enhance T cell and natural killer cell responses and inhibit tumor necrosis factor-α, interleukin (IL)-1β, and IL-12 production from LPS-stimulated peripheral blood mononuclear cells. However, the molecular mechanism of action for these compounds is unknown. Herein, we report on the ability of the IMiDs to up-regulate production of IL-2 from activated human CD4+ and CD8+ peripheral blood T cells, production of IL-2 and IFN-γ from T helper (Th)1-type cells, and production of IL-5 and IL-10 from Th2-type cells. Elevation of IL-2 production from Jurkat T cells was observed as early as 6 h poststimulation and correlated with an increase in IL-2 promoter activity that was dependent upon the proximal but not the distal AP-1 binding site. The IMiDs enhanced AP-1-driven transcriptional activity 2- to 4-fold after 6 h of T cell stimulation, and their relative potencies for AP-1 activation correlated with their potencies for increased IL-2 production in Jurkat T cells and in CD4+ or CD8+ human peripheral blood T cells. The most potent of these IMiDs, CC-4047, had no effect on nuclear factor of activated T cells transcriptional activity, calcium signaling, or phosphorylation of extracellular signal-regulated kinase 1/2, c-Jun NH2-terminal kinase 1/2, p38 mitogen-activated protein kinase, or c-Jun/Jun D in Jurkat T cells. These data suggest that IMiDs increase T cell cytokine production by potentiating AP-1 transcriptional activity.

[1]  Richard LeBlanc,et al.  Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. , 2002, Blood.

[2]  A. Dalgleish,et al.  Thalidomide and its analogues have distinct and opposing effects on TNF‐α and TNFR2 during co‐stimulation of both CD4+ and CD8+ T cells , 2002, Clinical and experimental immunology.

[3]  A. Dalgleish,et al.  Protective Antitumor Immunity Induced by a Costimulatory Thalidomide Analog in Conjunction with Whole Tumor Cell Vaccination Is Mediated by Increased Th1-Type Immunity , 2002 .

[4]  B. Aggarwal,et al.  Thalidomide Suppresses NF-κB Activation Induced by TNF and H2O2, But Not That Activated by Ceramide, Lipopolysaccharides, or Phorbol Ester1 , 2002, The Journal of Immunology.

[5]  M. Fresno,et al.  Phosphodiesterase 4 inhibitors prevent cytokine secretion by T lymphocytes by inhibiting nuclear factor-kappaB and nuclear factor of activated T cells activation. , 2001, The Journal of pharmacology and experimental therapeutics.

[6]  J. Rhodes,et al.  Schiff base‐mediated co‐stimulation primes the T‐cell‐receptor‐dependent calcium signalling pathway in CD4 T cells , 2001, Immunology.

[7]  G. Morgan,et al.  Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. , 2001, Blood.

[8]  A. Dalgleish,et al.  Immunotherapeutic and antitumour potential of thalidomide analogues , 2001, Expert opinion on biological therapy.

[9]  A. Baldwin,et al.  Inhibition of NF-κB Activity by Thalidomide through Suppression of IκB Kinase Activity* , 2001, The Journal of Biological Chemistry.

[10]  G. Tsokos,et al.  Protein Kinase C-θ Participates in the Activation of Cyclic AMP-Responsive Element-Binding Protein and Its Subsequent Binding to the −180 Site of the IL-2 Promoter in Normal Human T Lymphocytes1 , 2001, The Journal of Immunology.

[11]  B W Henderson,et al.  Activation of the IL-10 Gene Promoter Following Photodynamic Therapy of Murine Keratinocytes¶ , 2001, Photochemistry and photobiology.

[12]  A. Nel,et al.  The Physical Association of Protein Kinase Cθ with a Lipid Raft-Associated Inhibitor of κB Factor Kinase (IKK) Complex Plays a Role in the Activation of the NF-κB Cascade by TCR and CD281 , 2000, The Journal of Immunology.

[13]  G Muller,et al.  Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. , 2000, Blood.

[14]  H. Stockinger,et al.  SUPPRESSION OF PRIMARY T-CELL RESPONSES AND INDUCTION OF ALLOANTIGEN-SPECIFIC HYPORESPONSIVENESS IN VITRO BY THE JANUS KINASE INHIBITOR TYRPHOSTIN AG4901 , 2000, Transplantation.

[15]  P. Haslett,et al.  Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. , 1999, Journal of immunology.

[16]  J. Siekierka,et al.  p38α Mitogen-Activated Protein Kinase Is Activated by CD28-Mediated Signaling and Is Required for IL-4 Production by Human CD4+CD45RO+ T Cells and Th2 Effector Cells , 1999, The Journal of Immunology.

[17]  Gilla Kaplan,et al.  Amino-substituted thalidomide analogs: Potent inhibitors of TNF-α production , 1999 .

[18]  O. Kaminuma,et al.  Transcriptional control of the IL-5 gene by human helper T cells: IL-5 synthesis is regulated independently from IL-2 or IL-4 synthesis. , 1999, The Journal of allergy and clinical immunology.

[19]  F. Rohwer,et al.  IL-2-mediated cell cycle progression and inhibition of apoptosis does not require NF-kappa B or activating protein-1 activation in primary human T cells. , 1999, Journal of immunology.

[20]  J. Siekierka,et al.  T cell activation signals up-regulate p38 mitogen-activated protein kinase activity and induce TNF-alpha production in a manner distinct from LPS activation of monocytes. , 1999, Journal of immunology.

[21]  W. M. Weaver,et al.  The Roles of Nuclear Factor of Activated T Cells and Ying-Yang 1 in Activation-induced Expression of the Interferon-γ Promoter in T Cells* , 1998, The Journal of Biological Chemistry.

[22]  M R Jackson,et al.  Requirements for stimulating naive CD8+ T cells via signal 1 alone. , 1998, Journal of immunology.

[23]  P. Haslett,et al.  Thalidomide Costimulates Primary Human T Lymphocytes, Preferentially Inducing Proliferation, Cytokine Production, and Cytotoxic Responses in the CD8+ Subset , 1998, The Journal of experimental medicine.

[24]  F. Dumont,et al.  Inhibition of T cell activation by pharmacologic disruption of the MEK1/ERK MAP kinase or calcineurin signaling pathways results in differential modulation of cytokine production. , 1998, Journal of immunology.

[25]  Y. Sun,et al.  CD 80(B7-1) expression on human tumor cell lines and its costimulatory signals for T cell proliferation and cytokine production. , 1998, Chinese medical journal.

[26]  D. Cohen,et al.  Transcriptional regulation in the immune system: all roads lead to AP‐1 , 1998, Journal of leukocyte biology.

[27]  J. Siekierka,et al.  Nitroarylhydroxymethylphosphonic acids as inhibitors of CD45. , 1997, Bioorganic & medicinal chemistry.

[28]  N. Thompson,et al.  Convergence of Schiff base costimulatory signaling and TCR signaling at the level of mitogen-activated protein kinase ERK2. , 1997, Journal of immunology.

[29]  G. V. van Seventer,et al.  Human T helper cell differentiation is regulated by the combined action of cytokines and accessory cell-dependent costimulatory signals. , 1997, Journal of immunology.

[30]  J. Pober,et al.  Transcriptional Regulation of the Interleukin-2 Gene in Normal Human Peripheral Blood T Cells , 1996, The Journal of Biological Chemistry.

[31]  A. Sher,et al.  IL-12 inhibits Th2 cytokine responses induced by eggs of Schistosoma mansoni. , 1994, Journal of immunology.

[32]  H. Robinson,et al.  Two adjacent residues in staphylococcal enterotoxins A and E determine T cell receptor V beta specificity , 1993, The Journal of experimental medicine.

[33]  G. Crabtree,et al.  Identification of calcineurin as a key signalling enzyme in T-lymphocyte activation , 1992, Nature.

[34]  A. Rao,et al.  Analysis of the AP-1 sites in the IL-2 promoter. , 1992, Journal of immunology.

[35]  A. Kelso,et al.  Heterogeneity in Lymphokine Profiles of CD4+ and CD8+ T Cells and Clones Activated in vivo and in vitro , 1991, Immunological reviews.

[36]  Stuart L. Schreiber,et al.  Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes , 1991, Cell.

[37]  C. Griscelli,et al.  Inositol 1,4,5-trisphosphate- and arachidonic acid-induced calcium mobilization in T and B lymphocytes. , 1990, Cellular immunology.

[38]  M. Hagiwara,et al.  Inhibition of forskolin-induced neurite outgrowth and protein phosphorylation by a newly synthesized selective inhibitor of cyclic AMP-dependent protein kinase, N-[2-(p-bromocinnamylamino)ethyl]-5-isoquinolinesulfonamide (H-89), of PC12D pheochromocytoma cells. , 1990, The Journal of biological chemistry.

[39]  P. Lipsky,et al.  Accessory cell independent proliferation of human T4 cells stimulated by immobilized monoclonal antibodies to CD3. , 1987, Journal of immunology.